DK1397128T3 - Kappa-opiatagonist til behandling af irritabel blære - Google Patents
Kappa-opiatagonist til behandling af irritabel blæreInfo
- Publication number
- DK1397128T3 DK1397128T3 DK02724228T DK02724228T DK1397128T3 DK 1397128 T3 DK1397128 T3 DK 1397128T3 DK 02724228 T DK02724228 T DK 02724228T DK 02724228 T DK02724228 T DK 02724228T DK 1397128 T3 DK1397128 T3 DK 1397128T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- bladder
- kappa opiate
- opiate agonist
- irritable bladder
- Prior art date
Links
- 206010005052 Bladder irritation Diseases 0.000 title abstract 2
- 239000002632 kappa opiate receptor agonist Substances 0.000 title abstract 2
- 210000002700 urine Anatomy 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 230000003187 abdominal effect Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical compound C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 abstract 1
- 229950002202 asimadoline Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000007928 intraperitoneal injection Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002504 physiological saline solution Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10116978A DE10116978A1 (de) | 2001-04-05 | 2001-04-05 | Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase |
| PCT/EP2002/002756 WO2002080905A1 (de) | 2001-04-05 | 2002-03-13 | Kappa-opiatagonisten für die behandlung von erkrankungen der blase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1397128T3 true DK1397128T3 (da) | 2007-10-15 |
Family
ID=7680492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02724228T DK1397128T3 (da) | 2001-04-05 | 2002-03-13 | Kappa-opiatagonist til behandling af irritabel blære |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040157913A1 (cs) |
| EP (2) | EP1834640A3 (cs) |
| JP (1) | JP2004525165A (cs) |
| KR (1) | KR100851938B1 (cs) |
| CN (1) | CN1268332C (cs) |
| AT (1) | ATE366109T1 (cs) |
| AU (1) | AU2002254947B2 (cs) |
| BR (1) | BR0208488A (cs) |
| CA (1) | CA2443019C (cs) |
| CY (1) | CY1109001T1 (cs) |
| CZ (1) | CZ20032899A3 (cs) |
| DE (2) | DE10116978A1 (cs) |
| DK (1) | DK1397128T3 (cs) |
| ES (1) | ES2290286T3 (cs) |
| HU (1) | HUP0303910A3 (cs) |
| MX (1) | MXPA03009099A (cs) |
| MY (1) | MY136683A (cs) |
| PL (1) | PL363540A1 (cs) |
| PT (1) | PT1397128E (cs) |
| RU (1) | RU2307651C2 (cs) |
| SK (1) | SK13272003A3 (cs) |
| WO (1) | WO2002080905A1 (cs) |
| ZA (1) | ZA200308600B (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10259245A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
| EP1680115A1 (en) * | 2003-10-30 | 2006-07-19 | Tioga Pharmaceuticals, Inc. | Use of selective opiate receptor modulators in the treatment of neuropathy |
| SI2136801T1 (sl) | 2007-03-30 | 2013-01-31 | Tioga Pharmaceuticals, Inc. | Kappa-opiat agonisti za zdravljenje diareje-predominant in izmeniäśnega sindroma razdraĺ˝ljivih prebavil |
| EP2827852A4 (en) * | 2012-03-19 | 2016-03-02 | Wellesley Pharmaceuticals Llc | EXTENDED RELEASE FORMULATION FOR REDUCING BUBBLE HEAT FREQUENCY AND METHOD FOR USE THEREOF |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| CN112703000B (zh) | 2018-07-23 | 2024-05-31 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
| AU2021206252A1 (en) | 2020-01-10 | 2022-07-28 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| US6A (en) * | 1836-08-10 | Thomas Blanchard | Machine for forming end pieces of plank blocks for ships | |
| DE4215213A1 (de) * | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
| IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
| DE19523502A1 (de) * | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
| DE19531464A1 (de) * | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid |
| US5859043A (en) * | 1996-06-11 | 1999-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for maintaining kidney function during surgery or severe trauma under general anesthesia |
| US6201022B1 (en) * | 1997-03-27 | 2001-03-13 | Myorx, Inc. | Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid |
| US5965701A (en) * | 1997-12-23 | 1999-10-12 | Ferring Bv | Kappa receptor opioid peptides |
-
2001
- 2001-04-05 DE DE10116978A patent/DE10116978A1/de not_active Withdrawn
-
2002
- 2002-03-13 DE DE50210422T patent/DE50210422D1/de not_active Expired - Lifetime
- 2002-03-13 AT AT02724228T patent/ATE366109T1/de active
- 2002-03-13 ES ES02724228T patent/ES2290286T3/es not_active Expired - Lifetime
- 2002-03-13 BR BR0208488-0A patent/BR0208488A/pt not_active IP Right Cessation
- 2002-03-13 JP JP2002578944A patent/JP2004525165A/ja active Pending
- 2002-03-13 DK DK02724228T patent/DK1397128T3/da active
- 2002-03-13 AU AU2002254947A patent/AU2002254947B2/en not_active Ceased
- 2002-03-13 RU RU2003130641/14A patent/RU2307651C2/ru active
- 2002-03-13 CN CNB028073983A patent/CN1268332C/zh not_active Expired - Fee Related
- 2002-03-13 CZ CZ20032899A patent/CZ20032899A3/cs unknown
- 2002-03-13 HU HU0303910A patent/HUP0303910A3/hu unknown
- 2002-03-13 KR KR1020037012331A patent/KR100851938B1/ko not_active Expired - Fee Related
- 2002-03-13 US US10/474,312 patent/US20040157913A1/en not_active Abandoned
- 2002-03-13 CA CA002443019A patent/CA2443019C/en not_active Expired - Fee Related
- 2002-03-13 EP EP07111669A patent/EP1834640A3/de not_active Withdrawn
- 2002-03-13 EP EP02724228A patent/EP1397128B1/de not_active Expired - Lifetime
- 2002-03-13 PL PL02363540A patent/PL363540A1/xx unknown
- 2002-03-13 WO PCT/EP2002/002756 patent/WO2002080905A1/de active IP Right Grant
- 2002-03-13 MX MXPA03009099A patent/MXPA03009099A/es active IP Right Grant
- 2002-03-13 PT PT02724228T patent/PT1397128E/pt unknown
- 2002-03-13 SK SK1327-2003A patent/SK13272003A3/sk not_active Application Discontinuation
- 2002-04-02 MY MYPI20021192A patent/MY136683A/en unknown
-
2003
- 2003-11-04 ZA ZA200308600A patent/ZA200308600B/en unknown
-
2007
- 2007-09-25 CY CY20071101231T patent/CY1109001T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE50210422D1 (de) | 2007-08-16 |
| ES2290286T3 (es) | 2008-02-16 |
| EP1834640A2 (de) | 2007-09-19 |
| RU2307651C2 (ru) | 2007-10-10 |
| EP1397128A1 (de) | 2004-03-17 |
| KR100851938B1 (ko) | 2008-08-12 |
| MY136683A (en) | 2008-11-28 |
| DE10116978A1 (de) | 2002-10-10 |
| HUP0303910A3 (en) | 2005-04-28 |
| CN1268332C (zh) | 2006-08-09 |
| WO2002080905A1 (de) | 2002-10-17 |
| CZ20032899A3 (cs) | 2004-06-16 |
| CN1499967A (zh) | 2004-05-26 |
| MXPA03009099A (es) | 2004-02-12 |
| RU2003130641A (ru) | 2005-03-10 |
| CA2443019C (en) | 2009-12-29 |
| CA2443019A1 (en) | 2002-10-17 |
| SK13272003A3 (sk) | 2004-02-03 |
| AU2002254947B2 (en) | 2007-06-07 |
| BR0208488A (pt) | 2004-03-02 |
| HUP0303910A2 (hu) | 2004-03-29 |
| HK1064036A1 (en) | 2005-01-21 |
| EP1397128B1 (de) | 2007-07-04 |
| JP2004525165A (ja) | 2004-08-19 |
| PT1397128E (pt) | 2007-09-03 |
| KR20040025909A (ko) | 2004-03-26 |
| ZA200308600B (en) | 2004-09-13 |
| CY1109001T1 (el) | 2014-07-02 |
| EP1834640A3 (de) | 2009-12-23 |
| US20040157913A1 (en) | 2004-08-12 |
| PL363540A1 (en) | 2004-11-29 |
| ATE366109T1 (de) | 2007-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2864439B1 (fr) | Dispositif de traitement d'un volume de tissu biologique par hyperthermie localisee | |
| RU2015117267A (ru) | Замещенные соединения амида | |
| BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
| BRPI0416628A (pt) | uso de compostos orgánicos | |
| NO2012015I2 (no) | Dapoxetine | |
| BR0312785A (pt) | Tratamento de desordens relacionadas a tnf(alfa) | |
| EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
| BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
| BRPI0406592A (pt) | Usos de n-desmetilclozapina, métodos para o tratamento de psicose, de distúrbios afetivos, de demência, de dor neuropática e de glaucoma e composição farmacêutica | |
| BR0206160A (pt) | Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos | |
| DK1397128T3 (da) | Kappa-opiatagonist til behandling af irritabel blære | |
| IS2259B (is) | Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 undireiningunni | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| DE50110262D1 (de) | Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen | |
| BRPI0409359A (pt) | análogos quiméricos de somatostatina-dopamina | |
| EA200100009A1 (ru) | Способ лечения сахарного диабета | |
| BR0111982A (pt) | Tratamento com apomorfina, de disfunção sexual induzida por droga anti depressão | |
| IS8162A (is) | Aðferð til að meðhöndla eða fyrirbyggja neðri þvagvegaeinkenni | |
| WO2000076500A8 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| TW200512013A (en) | Gel formulation of oxybutynin hydrochloride | |
| WO2006012563A3 (en) | Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle | |
| RU2258473C1 (ru) | Способ хирургического формирования запирательного аппарата при отсутствии мышц анального сфинктера | |
| PL1514545T3 (pl) | Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich | |
| RU2001129092A (ru) | Способ Чернозубова И.Е. лечения заболеваний | |
| Richie et al. | By the way, doctor. Ultrasound treatment for Peyronie's disease? I have Peyronie's disease. Nothing seems to help. But I've heard about a new treatment that involves some kind of ultrasound. What do you think? |